Physician profile
Samuel Capouch
NPI 1326501750
$1,055.90
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $240 · 2024: $816.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,056.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,055.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $209.65 | 2023-2024 | Vumerity, Tysabri |
| Abbvie INC. | $189.99 | 2024 | |
| Novartis Pharmaceuticals Corporation | $153.46 | 2024 | |
| Pfizer INC. | $97.18 | 2023-2024 | |
| Livanova USA, INC. | $62.73 | 2024 | Vns Therapy Sentiva Model 1000 Generator |
| Ucb, INC. | $44.27 | 2023 | |
| Lilly USA, LLC | $43.14 | 2024 | Reyvow, Emgality, Amyvid |
| Argenx US, INC. | $43.06 | 2023-2024 | Vyvgart |
| Neurocrine Biosciences, INC. | $39.72 | 2024 | Ingrezza |
| Lundbeck LLC | $36.81 | 2023-2024 | Vyepti |
| Tg Therapeutics, INC. | $23.97 | 2024 | |
| Acorda Therapeutics, INC | $21.39 | 2023 | Ampyra, Inbrija |
| Grifols USA, LLC | $20.90 | 2024 | Gamunex-C |
| Abbott Laboratories | $19.85 | 2024 | Infinity |
| Emd Serono, INC. | $18.65 | 2023 | Mavenclad |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $18.01 | 2024 | Hizentra |
| Genentech USA, INC. | $13.12 | 2024 | Ocrevus |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel Capouch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.